According to the Complaint, this action stems from a proposed transaction announced on July 7, 2020 (the “Proposed Transaction”), pursuant to which National General Holdings Corp. (“National General” or the “Company”) will be acquired by The Allstate Corporation and Bluebird Acquisition Corp. On July 7, 2020, National General’s Board of Directors caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with Allstate. Pursuant to the terms of the Merger Agreement, National General’s stockholders will receive $32.00 in cash plus a special dividend equal to $2.50 in cash for each share of National General common stock they own.
Recent Security Class Actions
According to the Complaint, Kodak is a technology company that provides hardware, software, consumables, and services to customers in commercial print, packaging, publishing, manufacturing, and entertainment.
According to the Complaint, Cabot was incorporated in 1989 and is headquartered in Houston, Texas. Cabot is an independent oil and gas company that explores for, exploits, develops, produces, and markets oil and gas properties in the U.S.
According to the Complaint, Plaintiffs allege that in violation of the Exchange Act and in further violation of their fiduciary duties, Defendants caused to be filed with the SEC the materially deficient Preliminary Proxy on July 31, 2020 in an effort to solicit stockholders to vote their Churchill shares in favor of the Proposed Transaction. The Preliminary Proxy is materially deficient and deprives Churchill stockholders of the information they need to make an intelligent, informed and rational decision of whether to vote their shares in favor of the Proposed Transaction.
According to the Complaint, MEI Pharma was founded in 2000 and is based in San Diego, California. The Company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. MEI Pharma’s clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase inhibitor.
According to the Complaint, Airbus SE is a multinational aerospace corporation, operating through its Commercial Aircraft, Defense and Space, and Helicopters divisions.
According to the Complaint, GlobalSCAPE, Inc. secures and automates the movement and integration of data in, around, and outside organizations in and out of the cloud. Founded in 1996, the Company’s data exchange and integration software and cloud services are used by thousands of customers worldwide, including global enterprises, governments, and small and medium enterprises.
According to the Complaint, Rexahn Pharmaceuticals, Inc. is a biotechnology company that focuses on the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat.
According to the Complaint, Forescout Technologies, Inc. delivers device visibility and control to enable enterprises and government agencies to gain complete situational awareness of their environment and orchestrate action.
According to the Complaint, Velocity Financial, Inc. is a real estate finance company that primarily originates and manages loans secured by one-to-four unit residential retail and small commercial properties.
